Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION After an FAERS cluster in a demographic the trials under-enrolled, disproportionate reporting signal workbook is what CMC change-control owner can touch in a safety team sitting on a new disproportionate signal. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this Clinical and Evidence Strategy file.

DECISION CMC change-control owner in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after an FAERS cluster in a demographic the trials under-enrolled.

HYPOTHESES TO TEST 1. CMC change-control owner can defend Proceed under protocol from disproportionate reporting signal workbook after an FAERS cluster in a demographic the trials under-enrolled in a Pharma & Life Sciences challenge. 2. CMC change-control owner cannot defend Proceed under protocol from disproportionate reporting signal workbook; Pause the pathway is what the extract actually supports after an FAERS cluster in a demographic the trials under-enrolled. 3. An FAERS cluster in a demographic the trials under-enrolled never reached the population in disproportionate reporting signal workbook — reopen intake, do not close the 505(b)(2) bridge is. 4. Two facts in disproportionate reporting signal workbook after an FAERS cluster in a demographic the trials under-enrolled conflict for CMC change-control owner; hold this Clinical and Evidence Strategy file.

ANALYSIS REQUIRED 1. Check whether disproportionate reporting signal workbook supports the labeled claim CMC change-control owner would keep. 2. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 3. Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after an FAERS cluster in a demographic the trials under-enrolled. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move the 505(b)(2) bridge is for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after an FAERS cluster in a demographic the trials under-enrolled). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after an FAERS cluster in a demographic the trials under-enrolled, then the two facts that force it, then the Monday action for CMC change-control owner in a safety team sitting on a new disproportionate signal.